ASMB Assembly Biosciences, Inc.
Assembly Biosciences, Inc. (ASMB) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.5% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Assembly Biosciences, Inc.
Assembly Biosciences Inc, formerly Ventrus Biosciences Inc, is a pharmaceutical company. The Company is engaged in the late-stage clinical development of gastrointestinal products in areas of unmet need, anal fissures, and fecal incontinence.
Sector
Healthcare
Industry
Biotechnology